Tumor Stem Cell Assay

"Tumor Stem Cell Assay" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A cytologic technique for measuring the functional capacity of tumor stem cells by assaying their activity. It is used primarily for the in vitro testing of antineoplastic agents.

Descriptor ID	D014410
MeSH Number(s)	E01.370.225.500.383.910 E01.370.225.500.388.930 E05.200.500.383.910 E05.200.500.388.930 E05.242.383.910 E05.242.417.500 E05.337.550.200.800
Concept/Terms	Tumor Stem Cell Assay Tumor Stem Cell Assay Colony Forming Units Assay, Tumor Neoplasm Stem Cell Assay Stem Cell Assay, Tumor Clonogenic Cell Assay, Tumor Colony-Forming Units Assay, Tumor

Below are MeSH descriptors whose meaning is more general than "Tumor Stem Cell Assay".

Analytical, Diagnostic and Therapeutic Techniques and Equipment [E]
Diagnosis [E01]
Diagnostic Techniques and Procedures [E01.370]
Clinical Laboratory Techniques [E01.370.225]
Cytological Techniques [E01.370.225.500]
Colony-Forming Units Assay [E01.370.225.500.383]
Tumor Stem Cell Assay [E01.370.225.500.383.910]
Drug Screening Assays, Antitumor [E01.370.225.500.388]
Tumor Stem Cell Assay [E01.370.225.500.388.930]
Investigative Techniques [E05]
Clinical Laboratory Techniques [E05.200]
Cytological Techniques [E05.200.500]
Colony-Forming Units Assay [E05.200.500.383]
Tumor Stem Cell Assay [E05.200.500.383.910]
Drug Screening Assays, Antitumor [E05.200.500.388]
Tumor Stem Cell Assay [E05.200.500.388.930]
Cytological Techniques [E05.242]
Colony-Forming Units Assay [E05.242.383]
Tumor Stem Cell Assay [E05.242.383.910]
Drug Screening Assays, Antitumor [E05.242.417]
Tumor Stem Cell Assay [E05.242.417.500]
Evaluation Studies as Topic [E05.337]
Drug Evaluation, Preclinical [E05.337.550]
Drug Screening Assays, Antitumor [E05.337.550.200]
Tumor Stem Cell Assay [E05.337.550.200.800]

Below are MeSH descriptors whose meaning is related to "Tumor Stem Cell Assay".

Below are MeSH descriptors whose meaning is more specific than "Tumor Stem Cell Assay".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Tumor Stem Cell Assay" by people in this website by year, and whether "Tumor Stem Cell Assay" was a major or minor topic of these publications.

Bar chart showing 8 publications over 6 distinct years, with a maximum of 2 publications in 2008 and 2012

To see the data from this visualization as text, click here.

Year	Minor Topic	Total
1994	1	1
2008	2	2
2009	1	1
2010	1	1
2011	1	1
2012	2	2

Below are the most recent publications written about "Tumor Stem Cell Assay" by people in Profiles.

Zhang H, Peng C, Hu Y, Li H, Sheng Z, Chen Y, Sullivan C, Cerny J, Hutchinson L, Higgins A, Miron P, Zhang X, Brehm MA, Li D, Green MR, Li S. The Blk pathway functions as a tumor suppressor in chronic myeloid leukemia stem cells. Nat Genet. 2012 Jul 15; 44(8):861-71.

View in: PubMed
Brockschmidt A, Trost D, Peterziel H, Zimmermann K, Ehrler M, Grassmann H, Pfenning PN, Waha A, Wohlleber D, Brockschmidt FF, Jugold M, Hoischen A, Kalla C, Waha A, Seifert G, Knolle PA, Latz E, Hans VH, Wick W, Pfeifer A, Angel P, Weber RG. KIAA1797/FOCAD encodes a novel focal adhesion protein with tumour suppressor function in gliomas. Brain. 2012 Apr; 135(Pt 4):1027-41.

View in: PubMed
Cellurale C, Sabio G, Kennedy NJ, Das M, Barlow M, Sandy P, Jacks T, Davis RJ. Requirement of c-Jun NH(2)-terminal kinase for Ras-initiated tumor formation. Mol Cell Biol. 2011 Apr; 31(7):1565-76.

View in: PubMed
Liu X, Nakamura K, Wang Y, Cheng D, Liang M, Xiao N, Chen L, Rusckowski M, Hnatowich DJ. Auger-mediated cytotoxicity of cancer cells in culture by an 125I-antisense oligomer delivered as a three-component streptavidin nanoparticle. J Biomed Nanotechnol. 2010 Apr; 6(2):153-7.

View in: PubMed
Papi A, Tatenhorst L, Terwel D, Hermes M, Kummer MP, Orlandi M, Heneka MT. PPARgamma and RXRgamma ligands act synergistically as potent antineoplastic agents in vitro and in vivo glioma models. J Neurochem. 2009 Jun; 109(6):1779-90.

View in: PubMed
Zhou C, Nitschke AM, Xiong W, Zhang Q, Tang Y, Bloch M, Elliott S, Zhu Y, Bazzone L, Yu D, Weldon CB, Schiff R, McLachlan JA, Beckman BS, Wiese TE, Nephew KP, Shan B, Burow ME, Wang G. Proteomic analysis of tumor necrosis factor-alpha resistant human breast cancer cells reveals a MEK5/Erk5-mediated epithelial-mesenchymal transition phenotype. Breast Cancer Res. 2008; 10(6):R105.

View in: PubMed
Lambert LA, Qiao N, Hunt KK, Lambert DH, Mills GB, Meijer L, Keyomarsi K. Autophagy: a novel mechanism of synergistic cytotoxicity between doxorubicin and roscovitine in a sarcoma model. Cancer Res. 2008 Oct 01; 68(19):7966-74.

View in: PubMed
Calvo A, Catena R, Noble MS, Carbott D, Gil-Bazo I, Gonzalez-Moreno O, Huh JI, Sharp R, Qiu TH, Anver MR, Merlino G, Dickson RB, Johnson MD, Green JE. Identification of VEGF-regulated genes associated with increased lung metastatic potential: functional involvement of tenascin-C in tumor growth and lung metastasis. Oncogene. 2008 Sep 11; 27(40):5373-84.

View in: PubMed
Cahan MA, Walter KA, Colvin OM, Brem H. Cytotoxicity of taxol in vitro against human and rat malignant brain tumors. Cancer Chemother Pharmacol. 1994; 33(5):441-4.

View in: PubMed

People

Explore

Similar Concepts

Top Journals